Table 1.
Group-0 | Group-1 | Group-2 | Group-3 | Group-4 | |
---|---|---|---|---|---|
— | have TSH | 0.40 < TSH < 5.0 | TSH < 0.40 | TSH > 5.0 | |
Number of patients | 10 723 | 5112 | 3584 | 833 | 695 |
Sex | |||||
Female | 7562 (70%) | 3607 (71%) | 2538 (70%) | 615 (73%) | 454 (65%) |
Race and Ethnicity | |||||
White | 6935 (64%) | 2994 (59%) | 2100 (58%) | 544 (65%) | 350 (50%) |
Not Hispanic or Latino | 10 192 (95%) | 4846 (95%) | 3418 (95%) | 781 (93%) | 647 (93%) |
Age at IE | |||||
Mean (SD) (years) | 59 (16) | 58 (16) | 59 (16) | 55 (16) | 58 (17) |
Median (min, max) (years) | 61 (18, 92) | 60 (18, 91) | 61 (18, 91) | 56 (19, 90) | 59 (18, 91) |
Statin utilization | |||||
Before IE (%) | 14.3 | 18.3 | 19.1 | 15.2 | 17.7 |
After IE (%) | 17.7 | 23.4 | 24.6 | 19.2 | 22.7 |
Δ (percentage points) | 3.4 | 5.1 | 5.5 | 4.0 | 5.0 |
McNemar’s chi-squared test with continuity correction | |||||
chi-squared value | 247 | 298 | 319 | 5.6 | 42 |
P value | <.0001 | <.0001 | <.0001 | .0183 | <.0001 |
Serum TSH | |||||
Median (mIU/L) (25th, 75th percentile) | N/A | 1.89 (0.71, 3.4) | 1.97 (1.1,3.0) | 0.11 (0.03, 0.25) | 8.59 (6.1, 16) |
TSH assessment (weeks after IE) | |||||
Median (25th, 75th percentile) | N/A | 60 (32, 90) | 61 (33, 90) | 61 (37, 90) | 56 (25, 90) |
Started statin therapy (weeks after IE) | |||||
Median (25th, 75th percentile) | 49 (3, 109) | 75 (18, 122) | 76 (20, 121) | 77 (3, 126) | 70 (30, 120) |
Group 0, all patients that met inclusion/exclusion criteria; Group 1, patients with serum TSH levels at or around the time therapy with statins was initiated; Group 2, patients with normal serum TSH after the IE; Group 3, patients with suppressed TSH after the IE; Group 4, patients with elevated TSH after the IE. In the control group, statin utilization increased by 1.7 percentage points on year- 2 and by 3.8 percentage points on year 3.
Abbreviations: IE, index encounter; LT4, levothyroxine; SD, standard deviation; N/A, not all values are available; TSH, thyrotropin.